10X Genomics is a biotechnology company that specializes in genomic analysis, providing tools and technologies for researchers in the life sciences sector. The company develops innovative products that enable high-resolution analysis of biological systems, allowing scientists to explore complex interactions at the single-cell level. By offering advanced sequencing and gene expression solutions, 10X Genomics supports a wide range of applications in genomics, transcriptomics, and immunology, aiming to accelerate the discovery of new insights into health and disease. Read More
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Check out the companies making headlines this week: Qualcomm (NASDAQ:QCOM): Wireless chipmaker Qualcomm (NASDAQ:QCOM) fell by 4.7% on Wednesday after a lever...
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6.8% in the morning session after Barclays boosted its price target to $40 per shar...
The past six months have been a windfall for 10x Genomics’s shareholders. The company’s stock price has jumped 116%, setting a new 52-week high of $34.69 per...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
10x Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management c...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company’s h
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expec...
Biotech company 10x Genomics (NASDAQ:TXG) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The com...
Biotech company 10x Genomics (NASDAQ:TXG) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 mi...
Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after the bell. Here’s what to look for. 10x Genomics beat analys...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.4% in the afternoon session after a key industry peer, Thermo Fisher Scientific (TM...
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
